Introduction
============

Breast cancer is the most frequently diagnosed cancer among females worldwide following lung cancer [@B1]. Aberrant gene expression plays an important role in tumorigenesis, progression and metastasis of breast cancer and it is considered to be the consequence of not only genetic defects (such as TP53, PIK3CA mutation, BRCA1/BRCA2 inactivation, Cyclin D1 amplification [@B2]) but also epigenetic modifications [@B3]. Epigenetic alterations in breast cancer consist of DNA methylation, RNA methylation, histone modification , non-coding RNAs (especially miRNA and lncRNA) regulation and so no [@B4]. This study focused on DNA methylation, one of the most widely studied epigenetic modifications. DNA methylation occurs with the addition of a methyl (CH3) group from S-adenosylmethionine (SAM) into cytosine residues of the DNA template [@B5], mostly located on cytosine-phosphate-guanine (CpGs) dinucleotides. Both DNA hypermethylation and hypomethylation can be involved in diverse processes of breast cancer development and prognosis [@B6].

In clinical practice, though breast cancer is classified into three subtypes according to hormone receptor status, growth factor receptor status and Ki-67 which reflected partial prognostic information. And serum CA 15-3, CEA level, BRCA1/2 mutation status, PALB2 mutation status and circulating tumor DNA methylation might provide additional information for prognosis. However, heterogeneity of prognosis still exists. Therefore, more biomarkers are still urgently needed for more accurate prognosis. To date, there are many public databases for gene expression and methylation whose data was provided by published researches. Among them, plenty of researches have demonstrated the correlation between DNA methylation and prognosis of breast cancer, but the comprehensive profile and the interaction network of these aberrantly-expressed methylated genes still remain elusive. This study was aimed to identify aberrantly expressed hub genes that might be regulated by DNA methylation in breast cancer and to evaluate the prognostic value of these genes by using public databases. Several accessible software, databases, simple operations and basic bioinformatic knowledge were needed to complete this study and results might provide directions for further research.

Materials and Methods
=====================

Microarray and RNASeq data
--------------------------

In the initiation of present study, we screened the breast cancer expression microarray and methylation microarray datasets in GEO DataSets of NCBI (<https://www.ncbi.nlm.nih.gov/gds/>),sorted by sample number (From high to low). Study type was restricted to expression profiling by array and methylation profiling by array, and datasets both including breast cancer and normal breast samples were utilized. Finally, expression microarray datasets GSE54002, GSE65194 and methylation microarray datasets GSE20713, GSE32393 were included. 16 normal breast tissues and 200 primary breast cancer tissues were selected in GSE54002. 11 normal breast tissues and 130 primary breast cancer tissues were enrolled in GSE65194 (Platform: GPL570, Affymetrix Human Genome U133 Plus 2.0 Array). For methylation microarray dataset, GSE20713 enrolled 12 normal breast tissues and 234 primary breast cancer tissues. GSE32393 enrolled 23 normal breast tissues and 114 invasive breast tumor tissues. (Platform: GPL8490, Illumina HumanMethylation27 Bead Chip. HumanMethylation27_270596_v.1.2). For prognostic evaluation, GSE 65194 and GSE43568 datasets were included. 104 primary breast cancer tissues were enrolled in GSE43568 (Platform: GPL570, Affymetrix Human Genome U133 Plus 2.0 Array). As for RNASeq data, all normal and matched breast tumor level 3 mRNA expression HiSeq data sets (RNASeqV2) was obtained from The Cancer Genome Atlas (TCGA) (October 2015).

Screening for upregulated-hypomethylated and downregulated-hypermethylated genes
--------------------------------------------------------------------------------

GEO2R, an online analyzing tool of GEO DataSets, was utilized to analyze differentially expressed genes (DEG) between breast cancer tissues and normal tissues in expression microarray datasets and differential methylation in methylation microarray datasets. P value \< 0.05 and \|t\| \>2 were used as cutoff criteria to identify differential expression and methylation genes. Next, FunRich software (Functional Enrichment analysis tool, latest version 3.1.3 was download from <http://www.funrich.org/>) [@B7] was used to identify overlapping genes from GSE54002, GSE65194, GSE20713 and GSE32393. Finally, the overlapping genes were identified as upregulated-hypomethylated and downregulated-hypermethylated genes in breast cancer from the previous four datasets.

GO and KEGG pathway enrichment analysis
---------------------------------------

DAVID (The Database for Annotation, Visualization and Integrated Discovery, <https://david.ncifcrf.gov/>), an online analysis tool box consists of an integrated biological knowledgebase and analytic tools aimed at systematically extracting biological meaning from large gene/protein lists [@B8], was used for gene functional and pathway enrichment analysis. The gene ontology (GO) analysis [@B9] consisted of analysis of biological process (BP), cellular component (CC), molecular function (MF) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis [@B10] were performed for the identified downregulated-promotor hypermethylated genes. The top 5 GO analysis terms and top 10 KEGG pathways were visualized in the result. P value \< 0.05 was used as statistical significance.

Construction of protein-protein interaction (PPI) network and identification of hub genes
-----------------------------------------------------------------------------------------

STRING (Search Tool for the Retrieval of Interacting Genes, <https://string-db.org/>), an online protein interaction analysis tool, was performed to construct PPI network of the previous identified downregulated-promotor hypermethylated genes. Homo sapiens were selected as the organism for subsequent analysis. Medium confidence 0.4 of Interaction score was regarded as the cut-off criterion for network visualization and disconnected nodes was hidden. Subsequently, Cytoscape software (latest version 3.7.0, download from <http://www.cytoscape.org/>), a network data integration, analysis and visualization tool, was conducted to identify hub genes and modules within PPI network. Degree \>25 was used as cutoff criteria for hub gene identification. MCODE score \>3 and number of nodes \>4 were utilized as cutoff criteria for module identification.

Validation of gene expression in UALCAN database
------------------------------------------------

UALCAN (<http://ualcan.path.uab.edu/>), an online cancer transcriptome database, is designed to provide easy access to publicly available cancer transcriptome data (TCGA and MET500 transcriptome sequencing) [@B11]. This database was used to compare expression level of hub genes between normal breast tissue and primary invasive breast carcinoma.

Validation of gene methylation in MethHC database
-------------------------------------------------

MethHC (<http://MethHC.mbc.nctu.edu.tw>), a database of DNA Methylation and gene expression in Human Cancer, integrates data from TCGA (The Cancer Genome Atlas), which includes 18 human cancers in more than 6000 samples, 6548 microarrays and 12 567 RNA sequencing data. Differential DNA methylation was compared by average beta value in tumor sample and matched normal samples in different genes [@B12].

Survival analysis of genes in Kaplan Meier-plotter database
-----------------------------------------------------------

Clinical outcome analysis of hub genes in breast cancer was performed by Kaplan Meier-plotter database [@B13] whose background database was established using gene expression data and survival information of 1,809 patients downloaded from GEO (Affymetrix HGU133A and HGU133+2 microarrays). Overall survival analysis of 16 hub genes was performed separately in its default settings with 300 months follow-up.

COX regression analysis and Kaplan Meier-plotter construction
-------------------------------------------------------------

IBM SPSS statistics 22 was used for cox regression analysis. Relative ratio (RR) and 95% CI were used for statistical analysis. After univariable analysis, hub genes were enrolled in multivariable analysis whose p value \<0.1. Backward regression was used for multivariable regression analysis. Finally, hub genes included in the last step was selected as combined genes for prognostic analysis. Next, the upper 50% gene expression patient was defined as high expression group and lower 50% gene expression was defined as low expression group. Exp(B) from multivariable analysis was saved for the following classification. The upper 50% RR was defined as high risk group and lower 50% was defined as low risk group. ROC curve analysis was performed for single gene and combine genes group for predicting 5-year overall survival. Kaplan Meier-plotter analysis was performed for specific group identified previously. Log Rank (Mantel-Cox) was used for statistical analysis.

Tissue microarrays (TMAs) and IHC staining
------------------------------------------

TMAs were purchased from Outdo Biotech (Shanghai, China), and contained 140 breast cancer samples. But 7 samples were missing after we finished IHC staining. Clinicopathological characteristics of these 133 samples are listed in [Table S2](#SM0){ref-type="supplementary-material"}. This experiment was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine. Primary antibodies against EXO1 (Huabio, ER1908-42, China) (1:200) was used for IHC staining.

EXO1 expression scores were blindly evaluated by two pathologists using the immunoreactivity score (IRS), based on the percentage of positive cells and the intensity of staining. When the two pathologists had a very different score, we asked a third pathologist to evaluate the slide. The percentage of positive cells was graded as follows: 0 (negative), 1 (\<10%), 2 (10%-50%), 3 (51%-80%), 4 (\>80%). The intensity of staining was graded as follows: 0 (no color reaction), 1 (mild reaction), 2 (moderate reaction), 3 (intense reaction). IRS was multiplied by the two scores. In this study, EXO1 expression was defined as low (IRS ≤6) or high (IRS \>6).

Results
=======

Identification of abnormal expressed-methylated genes in breast cancer
----------------------------------------------------------------------

GEO2R, an online analyzing tool of GEO DataSets, was utilized to screen differentially expressed genes in expression microarray (GSE54002, GSE65194), and differentially methylated genes in methylation microarray (GSE20713, GSE32393), separately. As a result, 9945 upregulated, 4857 downregulated genes from GSE54002 and 6074 upregulated, 8714 downregulated genes from GSE65194 were identified. For methylation microarray data, 2075 hypermethylation, 8282 hypomethylation genes from GSE20713 and 3752 hypermethylation, 2750 hypomethylation genes from GSE32393 were identified. 677 upregulated-hypomethylation genes (Fig. [1](#F1){ref-type="fig"}A) and 361 downregulated-hypermethylation genes (Fig. [1](#F1){ref-type="fig"}B) were sorted out by overlapping genes from four GSE datasets using FunRich software. These 1038 genes were identified as aberrantly expressed-methylated genes in breast cancer.

GO functional enrichment analysis
---------------------------------

Functional enrichment analysis of 677 upregulated-hypomethylation genes and 361 downregulated-hypermethylation genes was performed by GO analysis. The result was listed in Table [1](#T1){ref-type="table"}. The top 5 terms of analytical result including biological process, cellular component and molecular function, were visualized in the table ranking by P-value from low to high (p\<0.05). The most significant biological process, cellular component and molecular function enriched in the 677 upregulated-hypomethylation genes was viral process, cytoplasm and protein binding, separately. For downregulated-hypermethylated genes, the result was peptidyl-tyrosine phosphorylation, plasma membrane, transmembrane receptor and protein tyrosine kinase activity, separately.

KEGG pathway enrichment analysis
--------------------------------

The top 10 KEGG pathways enriched by DAVID were demonstrated in Table [2](#T2){ref-type="table"} by P-value from low to high (p\<0.05). The most significant pathway enriched in 677 upregulated-hypomethylation genes was Pathways in cell cycle, including 16 genes (YWHAZ, E2F5, ANAPC13, DBF4, TTK, CDK6, PTTG1, CDC27, MCM4, MCM5, CCNE2, CCND1, CDKN2A, MCM7, MAD2L1, BUB3). For 361 downregulated-hypermethylation genes, the most significant pathway enriched was Rap1 signaling pathway, including 16 genes (EGFR, FGFR1, MAGI2, FGF7, FLT1, PGF, MRAS, GRIN2A, KIT, CALML3, PDGFRA, RAP1A, GNAS, FGF2, INSR, PIK3R1). Famous pathways P53, PI3K-Akt, and Ras signaling pathway which play important roles in life process were also enriched in KEGG pathway analysis.

PPI network construction and hub gene validation
------------------------------------------------

PPI network was constructed by STRING database and hub gene validation was identified by Cytoscape software. Module analysis was performed by MCODE, an application in Cytoscape software. PPI network was displayed in [Fig. S1](#SM0){ref-type="supplementary-material"} and [Fig.S2](#SM0){ref-type="supplementary-material"}. Different color of nodes and edges meat for different known status for proteins and different protein-protein association strength. Five modules for upregulated-hypomethylated genes ([Fig. S1](#SM0){ref-type="supplementary-material"}B-F) and 3 modules for downregulated-hypermethylated genes ([Fig. S2](#SM0){ref-type="supplementary-material"}B-D) were identified in the PPI network according to the cutoff of MCODE score \>3 and number of nodes \>4. 16 hub gene were identified by the cutoff criteria of degree \>25 (Table. [3](#T3){ref-type="table"}), 12 genes for upregulated-hypomethylated and 4 genes for downregulated-hypermethylated genes group.

Expression validation of the hub genes in TCGA dataset through UALCAN database
------------------------------------------------------------------------------

In order to validate the expression status of 16 hub genes in breast cancer compared to normal breast tissue, UALCAN database was utilized to confirmed the result. All of the 16 hub genes were found to be significantly differential expressed in invasive breast carcinoma. 12 upregulated hub genes (TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) identified from GSE database were confirmed to be high expression genes in breast cancer (Fig. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) (p\<0.05) and 4 downregulated hub genes (EGFR, FGF2, BCL2, PIK3R1) confirmed to be low expression genes (Fig. [4](#F4){ref-type="fig"}) (p\<0.05). P values for those genes were listed in Table. [3](#T3){ref-type="table"}. What\'s more, we compared expression of 16 hub genes using breast cancer RNASeq data downloaded from TCGA and the result was consistent with the previous data ([Fig. S3](#SM0){ref-type="supplementary-material"}).

Validation of DNA methylation in 16 hub genes in TCGA dataset through MethHC
----------------------------------------------------------------------------

DNA methylation status was validated in MethHC database. 7 in 12 upregulated hub genes (TOP2A, EPRS, EXO1, PTTG1, RRM2, PSMD14, H2AFZ) were found to be promoter hypomethylated (Fig. [5](#F5){ref-type="fig"}) and 2 in 4 downregulated genes (EGFR, FGF2) were validated to be promoter hypermethylated (Fig. [6](#F6){ref-type="fig"}). There was no significance of DNA promoter methylation between invasive breast cancer and normal breast tissues in 4 upregulated hub genes (MAD2L1, FEN1, CDKN3, CCN2) (Fig. [5](#F5){ref-type="fig"}). In contrast, MCM4 gene promoter was hypermethylated in breast cancer (Fig. [5](#F5){ref-type="fig"}) and BCL2, PIK3R1 gene promoter were hypomethylated (Fig. [6](#F6){ref-type="fig"}). DNA methylation status of hub genes and P values was listed in Table [3](#T3){ref-type="table"}.

Clinical outcome due to differential expression of the hub genes
----------------------------------------------------------------

To analyze prognostic value of 16 differentially expressed-methylated hub genes of breast cancer, Kaplan Meier-plotter database restricted to breast cancer was searched. Upregulation of TOP2A, MAD2L1, FEN1, EPRS (Fig. [7](#F7){ref-type="fig"}), EXO1, MCM4, PTTG1, RRM2 (Fig. [8](#F8){ref-type="fig"}), PSMD14, CDKN3, H2AFZ, CCNE2 (Fig. [9](#F9){ref-type="fig"}) and downregulation of FGF2, BCL2, PIK3R1 were significantly associated with poor overall survival, but downregulation of EGFR was not (Fig. [10](#F10){ref-type="fig"}). Among the 16 hub genes, upregulation of MAD2L1 was associated with unfavorable OS most significantly (HR=2.02 (1.62-2.51), P =1.8e-10).

What\'s more, we analyzed prognostic value of combined genes by using GSE42568 and GSE65194 datasets. Univariable cox regression analysis was performed first and we found that overexpression of MAD2L1, EXO1, MCM4, PTTG1 and CDKN3 was significantly associated with poor OS in GSE42568 dataset. Overexpression of EXO1, PTTG1, CCNE2 and PIK3R1 was significantly associated with poor OS in GSE65194 ([Table S1](#SM0){ref-type="supplementary-material"}) (p\<0.05). TOP2A, MAD2L1, EXO1, MCM4, PTTG1, CDKN3 and CCNE2 in GSE42568 and TOP2A, FEN1, EXO1, MCM4, PTTG1, RRM2, CCNE2 in GSE65194 were enrolled in multivariable cox regression analysis whose p \<0.1. Finally, EXO1, MCM4 and EXO1, PTTG1 were selected as combined gene group in GSE42568 and GSE65194 separately according to the final step of multivariable cox regression analysis. RR and 95% CI of univariable and multivariable cox analysis was listed in [Table S1](#SM0){ref-type="supplementary-material"}. Further, we classified patients into high expression and low expression group by single gene expression status. For combined gene group classification, we divided patients into two groups by relative ratio of multivariable analysis. ROC analysis for predicting 5-year overall survival was performed. AUC for combined group was equal to EXO1 in both datasets. Kaplan Meier-plotter was constructed for the previous identified groups. Prognostic value of combined EXO1 and MCM4 was no better than EXO1 in both datasets ([Figure S4](#SM0){ref-type="supplementary-material"}).

Prognosis in patients with protein expression of EXO1
-----------------------------------------------------

Since high EXO1 mRNA expression was identified as a strong individual prognostic factor in the previous part. Then, we performed IHC to investigated if EXO1 protein levels were significantly associated with OS in breast cancer patients.

Finally, there were 133 of 140 tumor samples used for EXO1 protein expression analysis since 7 samples were missing in the process of IHC staining within the TMAs. Representative images of EXO1 low and high expression were shown (Fig.[11](#F11){ref-type="fig"}A). EXO1 was mainly expressed in nuclear. 48.1% (64 of 133) patients exhibited EXO1 high expression (IRS \>6). Median follow-up time was 123 months. For survival analysis, Kaplan-Meier analysis showed that high EXO1 protein expression was significantly associated with decreased OS in breast cancer patients (p=0.03, Fig. [11](#F11){ref-type="fig"}B). There were no differences in clinical Clinicopathological characteristics between EXO1 high expression and low expression cohorts ([Table S2](#SM0){ref-type="supplementary-material"}). The results suggested that in protein levels, high EXO1 expression was correlated with poor OS.

Discussion
==========

Recurrence and drug resistance are the main causes of mortality in breast cancer [@B14], therefore it is of great significance to evaluate the prognosis precisely and individually before progression. In this study, we discovered 677 upregulated-hypomethylated and 361 downregulated-hypermethylated genes from GSE54002, GSE65194, GSE20713 and GSE32393 by GEO2R and FunRich. Among them, 12 upregulated hub genes and 3 downregulated genes turn out to contribute to significant adverse clinical outcome in breast cancer.

As was suggested in KEGG pathway enrichment analysis by DAVID, MAD2L1, PTTG1, MCM4 and CCNE2 are both involved in cell cycle pathway. MAD2L1 is a mitotic spindle checkpoint gene. Among patients with primary breast cancer, higher expression of MAD2L1 and BUB1 existed in patients with ER-, PR-, and high-grade tumors compared to those with ER +, PR+, and low-grade tumors. High MAD2L1 expression was associated with poor overall survival [@B15], which is consistent with our results. PTTG1 is a regulator in chromosomal segregation. It can promote the proliferation of breast cancer cell through binding to P27 directly to induce nuclear exclusion of P27 [@B16]. MCM4 gene encodes a kind of minichromosomal maintenance proteins. MCM4 overexpression was found only weakly associated with shorter survival in breast cancer alone while the MCM complex had a better prognosis value [@B17]. CCNE2 is known to promote G1-S transition. It has been demonstrated that CCNE2, targeted by miR-26a, miR-30b, might play an important role in acquired trastuzumab resistance in HER2+ breast cancer [@B18]. TOP2A and RRM2 are both essential enzyme in DNA replication. TOP2A amplification often occurs with HER2 amplification [@B19]. Previous researches have confirmed that upregulated TOP2A has unfavorable prognosis in breast cancer in both 5-year disease-free survival [@B20] and adjuvant treatment [@B21]. High expression of RRM2 was associated significantly with decreased survival in all breast cancer subtypes and increased expression was shown in tamoxifen-resistant patients [@B22]. Moreover, RRM2 can be targeted and suppressed by miR‐204‐5p and RRM2 overexpression can promote the proliferation and metastasis of breast cancer cells and suppressed cell apoptosis [@B23]. FEN1 and CDKN3 are tumor suppressor genes while elevated expression of these genes may not seem to protect against carcinogenesis.

FEN1 is a DNA repair-specific nuclease. High level of FEN1 expression in breast cancer cells could reflect the enhanced proliferation or increased DNA damage of cancer cells [@B24]. The level of FEN1 is inversely associated with cancer drug and radiation resistance [@B25]. YY1[@B25] and Nrf2 [@B26] can down-regulated FEN1 expression through binding to the FEN1 promoter region and inactivating it. CDKN3 is involved in mitosis. Overexpression of CDKN3 predicts poor prognosis in cervical cancer [@B27] and lung adenocarcinoma [@B28] and it is also an effective biomarker in digestive system carcinomas [@B29], [@B30]. However, there are not many relative researches about CDKN3 in breast cancer. EPRS is one of the Aminoacyl-tRNA synthetases, which are involved in protein translation. EPRS copy number gains in breast cancers tumors [@B31]. Additionally, EPRS was selectively carbonylated in tumor tissue compared to matched adjacent healthy tissue in breast cancer [@B32]. EXO1 is an exonuclease, which belongs to the mismatch repair system. EXO1 plays a role in replication fork degradation in BRCA1-and BRCA2-deficient cells [@B33]. A meta-analysis of transcriptomic data of primary breast tumors also supports our finding about EXO1 [@B34].

PSMD14 is a kind of deubiquitinating enzymes. There are few researches on PSMD14 in breast cancer. While recent studies have shown that high expression level of PSMD14 predicts poor prognosis of human esophageal squamous cell carcinoma [@B35]. H2AFZ is an oncogenic histone variant that is expressed independently of DNA replication. SMYD3-mediated H2AFZ methylation accelerates G1-S transition and promotes breast cancer proliferation [@B36].

4 downregulated-hypermethylated hub genes (EGFR, FGF2, BCL2, PIK3R1) were sorted out by PPI network, and 3 of them turned out to be significantly associated with poor overall survival except EGFR. EGFR is a commonly mutant gene in many malignant tumors. EGFR is often overexpressed in breast cancer, especially in triple-negative breast cancer [@B37], while hypermethylation of EGFR can contribute to cetuximab resistance [@B38]. FGF2 involves in cell proliferation and angiogenesis. FGF2 is hypermethylated in HR+ breast cancers and may have prognosis value [@B39] while it has low prognosis implication in triple-negative breast cancer [@B40]. BCL2 belongs to the anti-apoptotic and anti-proliferative. A lot of studies have proved that positive BCL2 shows better prognosis in breast cancer [@B41]-[@B43]. Therefore, we can infer that down-regulated expression of BCL2 predicts unfavorable prognosis.

PIK3R1 encodes the p85α regulatory subunit which regulates and stabilizes p110α. PIK3R1 has a lower frequency mutation than PIK3CA in breast cancer [@B2]. Previous studies have confirmed that Low expression of PIK3R1 is associated with poor prognosis [@B44], [@B45].The prognosis value of some genes has been practiced in previous studies which is in accordance with our findings but more validation studies will still be needed. And the rest also needs to be explored in the future.

To the best of our knowledge, this is the first study to screen the differentially expressed-aberrantly methylated hub genes of significant prognosis value in breast cancer by simple bioinformatics. In this study, 4 microarray datasets were used to screen these genes to make the results much more convincing. Moreover, databases from TCGA dataset were used to validate the expression and DNA methylation of these 16 hub genes. In addition, the prognosis values of the 16 genes in breast cancer were analyzed through Kaplan Meier-plotter database. Except EFGR, other 15 differently-expressed genes are all significantly associated with prognosis. Also, the KEGG pathway analysis of these hub genes can provide guidance for further researches in breast cancer. What\'s more, we analyzed the prognostic value of combined genes and found that it was no better than EXO1 in both datasets. Not enough patients in either dataset or overexpression of EXO1 which was really a strong prognostic factor may cause this result. Protein levels of EXO1 were also analyzed and we found that high expression of EXO1 was associated with significant poor OS which suggested that EXO1 was a competitive prognostic factor for clinical application.

However, there were still some limitations in this study should be acknowledged. Though, expression of these genes were all remained to be significantly upregulated or downregulated after validation in UALCAN database, but only 7 of 12 hypomethylated and 2 of 4 hypermethylated genes was validated in another methylation database. Expression analysis may be more stable across different database. However, methylation status of some genes was varied among different platforms and databases. In our study, two methylation microarray datasets were performed on the same platform (Illumina HumanMethylation27 Bead Chip) in order to eliminate platform diversity and using another methylation database to make the result more convincing.

Conclusion
==========

In general, our study identified 9 aberrantly expressed-methylated hub genes in breast cancer significantly contributing to poor prognosis by bioinformatic analysis. Functional analysis and pathway enrichment analysis of those genes would provide novel ideas for further breast cancer research. 12 upregulated hub genes (TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) and 4 downregulated hub genes (EGFR, FGF2, BCL2, PIK3R1) might serve as diagnosis and poor prognosis biomarkers in breast cancer in the future by more research validation. Especially, EXO1 was identified as an individual unfavorable prognostic factor in this research.
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![Expression validation in UALCAN database for upregulated-hypomethylated hub genes (Data from TCGA database). A: PTTG1; B: RRM2; C: PSMD14; D: CDKN3; E: H2AFZ; F: CCNE2. \*\*\*: p\<0.001.](jcav10p6618g003){#F3}

![Expression validation in UALCAN database for downregulated-hypermethylated hub genes (Data from TCGA database). A: EGFR; B: FGF2; C: BCL2; D: PIK3R1. \*\*\*: p\<0.001.](jcav10p6618g004){#F4}

![Validation of DNA methylation in upregulated hub genes in TCGA dataset through MethHC database. (A-L) Expression of upregulated-hypomethylated hub genes. A: TOP2A; B: MAD2L1; C: FEN1; D: EPRS; E: EXO1; F: MCM4, G: PTTG1; H: RRM2; I: PSMD14; J: CDKN3; K: H2AFZ; L: CCNE2. Green column: Normal breast tissue; Red column: invasive breast cancer. \* p \<0.05; \*\* p \<0.005.](jcav10p6618g005){#F5}
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![Prognostic values of upregulated hub genes in breast cancer (Kaplan Meier-plotter database). A: EXO1; B: MCM4; C: PTTG1; D: RRM2.](jcav10p6618g008){#F8}

![Prognostic values of upregulated hub genes in breast cancer (Kaplan Meier-plotter database). A: PSMD14; B: CDKN3; C: H2AFZ; D: CCNE2.](jcav10p6618g009){#F9}
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![Prognostic significances of EXO1 protein expression in breast cancer. (A). Immunohistochemical analysis of EXO1 in breast cancer tissue with low staining and high staining; (B) Kaplan-Meier OS analysis of EXO1 protein expression in breast cancer patients. (Each tissue section was observed under microscopy with low magnification of 50× and high magnification of 100×.)](jcav10p6618g011){#F11}

###### 

GO functional analysis of biological process, cell component and molecular function of differentially expressed-methylated genes.

  Category                                  GO Analysis        Term                                                                  Count   \%     P Value
  ----------------------------------------- ------------------ --------------------------------------------------------------------- ------- ------ ----------
  **Hypomethylation and high expression**   GOTERM_BP_DIRECT   GO:0016032\~viral process                                             32      0.03   4.25E-07
                                                               GO:0009615\~response to virus                                         16      0.01   1.75E-05
                                                               GO:0032508\~DNA duplex unwinding                                      10      0.01   3.36E-05
                                                               GO:0032727\~positive regulation of interferon-alpha production        6       0.01   4.94E-05
                                                               GO:0006281\~DNA repair                                                23      0.02   9.42E-05
                                            GOTERM_CC_DIRECT   GO:0005737\~cytoplasm                                                 278     0.26   1.27E-13
                                                               GO:0005829\~cytosol                                                   196     0.18   4.83E-13
                                                               GO:0016020\~membrane                                                  139     0.13   5.21E-11
                                                               GO:0005654\~nucleoplasm                                               163     0.15   2.50E-10
                                                               GO:0070062\~extracellular exosome                                     152     0.14   2.54E-07
                                            GOTERM_MF_DIRECT   GO:0005515\~protein binding                                           451     0.41   3.08E-23
                                                               GO:0004003\~ATP-dependent DNA helicase activity                       11      0.01   1.61E-07
                                                               GO:0005524\~ATP binding                                               89      0.08   1.51E-05
                                                               GO:0044822\~poly(A) RNA binding                                       68      0.06   1.35E-04
                                                               GO:0042802\~identical protein binding                                 47      0.04   7.65E-04
  **Hypermethylation and low expression**   GOTERM_BP_DIRECT   GO:0018108\~peptidyl-tyrosine phosphorylation                         17      0.03   8.05E-08
                                                               GO:0010863\~positive regulation of phospholipase C activity           5       0.01   1.88E-05
                                                               GO:0030335\~positive regulation of cell migration                     15      0.03   2.22E-05
                                                               GO:0007568\~aging                                                     13      0.02   1.31E-04
                                                               GO:0007155\~cell adhesion                                             23      0.04   1.64E-04
                                            GOTERM_CC_DIRECT   GO:0005886\~plasma membrane                                           119     0.21   7.89E-07
                                                               GO:0005615\~extracellular space                                       52      0.09   1.98E-06
                                                               GO:0005829\~cytosol                                                   92      0.16   1.29E-04
                                                               GO:0005925\~focal adhesion                                            20      0.04   2.00E-04
                                                               GO:0042383\~sarcolemma                                                9       0.02   2.19E-04
                                            GOTERM_MF_DIRECT   GO:0004714\~transmembrane receptor protein tyrosine kinase activity   9       0.02   6.30E-07
                                                               GO:0004713\~protein tyrosine kinase activity                          14      0.02   2.39E-06
                                                               GO:0046934\~phosphatidylinositol-4,5-bisphosphate 3-kinase activity   9       0.02   2.88E-05
                                                               GO:0043548\~phosphatidylinositol 3-kinase binding                     5       0.01   4.61E-04
                                                               GO:0005088\~Ras guanyl-nucleotide exchange factor activity            10      0.02   4.67E-04

###### 

KEGG pathway enrichment analysis of differentially expressed-methylated genes.

  Pathway ID                                Pathway name                                  Gene Count   \%     PValue     Genes
  ----------------------------------------- --------------------------------------------- ------------ ------ ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  **Hypomethylation and high expression**                                                                                
  hsa04110                                  Cell cycle                                    16           0.01   6.73E-04   YWHAZ, E2F5, ANAPC13, DBF4, TTK, CDK6, PTTG1, CDC27, MCM4, MCM5, CCNE2, CCND1, CDKN2A, MCM7, MAD2L1, BUB3
  hsa03050                                  Proteasome                                    9            0.01   8.90E-04   PSMB5, PSMB4, PSMD14, PSMD12, PSMC2, SHFM1, PSMD1, PSMD4, PSMB9
  hsa04115                                  p53 signaling pathway                         10           0.01   0.00       CCNE2, PPM1D, CCND1, CDKN2A, RRM2, CYCS, CDK6, APAF1, THBS1, PERP
  hsa03030                                  DNA replication                               7            0.01   0.01       RFC3, MCM7, SSBP1, POLD1, MCM4, MCM5, FEN1
  hsa04141                                  Protein processing in endoplasmic reticulum   16           0.01   0.01       RAD23B, DERL1, MAN1A2, NSFL1C, UBQLN1, ATF6, DNAJB11, FBXO6, DNAJB1, SAR1A, DNAJC1, SEC61A1, SSR2, SEC23B, SEC61G, SEL1L
  hsa05152                                  Tuberculosis                                  16           0.01   0.02       RFX5, ATP6AP1, IL18, CEBPG, CYCS, ITGB2, ARHGEF12, ATP6V0B, CD74, VDR, MYD88, MAPK13, RIPK2, HSPD1, APAF1, FCGR3B
  hsa03060                                  Protein export                                5            0.00   0.02       SRPRB, SRP72, SRP9, SEC61A1, SEC61G
  hsa05169                                  Epstein-Barr virus infection                  12           0.01   0.03       DDX58, ICAM1, PSMD14, PSMD12, CD44, MAPK13, NFKBIE, PSMC2, SHFM1, PSMD1, PSMD4, TRAF5
  hsa04623                                  Cytosolic DNA-sensing pathway                 8            0.01   0.03       DDX58, POLR3K, POLR2K, IL18, IRF7, AIM2, CXCL10, ADAR
  hsa05203                                  Viral carcinogenesis                          17           0.02   0.03       HPN, YWHAZ, HIST1H2BC, HIST1H2BD, SP100, UBE3A, GTF2H4, CDK6, CCNE2, CCND1, KRAS, CDKN2A, HIST2H2BE, IRF7, HDAC8, TRAF5, DLG1
  **Hypermethylation and low expression**                                                                                
  hsa04015                                  Rap1 signaling pathway                        16           0.03   9.42E-05   EGFR, FGFR1, MAGI2, FGF7, FLT1, PGF, MRAS, GRIN2A, KIT, CALML3, PDGFRA, RAP1A, GNAS, FGF2, INSR, PIK3R1
  hsa04014                                  Ras signaling pathway                         16           0.03   2.13E-04   EGFR, FGFR1, PLD1, FGF7, FLT1, PGF, RALBP1, MRAS, GRIN2A, KIT, CALML3, PDGFRA, RAP1A, FGF2, INSR, PIK3R1
  hsa05200                                  Pathways in cancer                            22           0.04   2.55E-04   EGFR, FGFR1, FGF7, WNT5B, PGF, RALBP1, STAT5A, STAT5B, RUNX1T1, KIT, DAPK2, LAMA2, LAMA1, EDNRB, BCL2, PDGFRA, JAK1, NKX3-1, GNAS, FGF2, PIK3R1, APC
  hsa04510                                  Focal adhesion                                14           0.02   9.15E-04   EGFR, FLT1, PGF, ITGA1, ITGA10, MYL9, LAMA2, LAMA1, BCL2, PDGFRA, RAP1A, RELN, MYLK, PIK3R1
  hsa04151                                  PI3K-Akt signaling pathway                    19           0.03   9.56E-04   EGFR, FGFR1, FLT1, SGK2, FGF7, PGF, ITGA1, ITGA10, KIT, LAMA2, LAMA1, TSC1, BCL2, PDGFRA, JAK1, RELN, FGF2, INSR, PIK3R1
  hsa04810                                  Regulation of actin cytoskeleton              14           0.02   1.09E-03   EGFR, FGFR1, FGF7, ARHGEF7, MRAS, ITGA1, ITGA10, MYL9, PDGFRA, MSN, FGF2, MYLK, PIK3R1, APC
  hsa04640                                  Hematopoietic cell lineage                    8            0.01   3.84E-03   CD9, CR1, CD59, ITGA1, MME, KIT, IL11RA, IL1A
  hsa05230                                  Central carbon metabolism in cancer           6            0.01   0.02       EGFR, NTRK3, FGFR1, PDGFRA, KIT, PIK3R1
  hsa04270                                  Vascular smooth muscle contraction            8            0.01   0.02       ACTG2, CALML3, ACTA2, ADRA1A, GNAS, MYLK, PPP1R14A, MYL9
  hsa04610                                  Complement and coagulation cascades           6            0.01   0.02       CR1, A2M, C3, F3, CD59, SERPING1

###### 

Expression validation of 12 upregulated-hypomethylation and 4 downregulated-promotor hypermethylation hub genes by UALCAN.

  Category                                  Hubgenes   Gene description                                 Degree   Expression status   P value
  ----------------------------------------- ---------- ------------------------------------------------ -------- ------------------- ----------
  **Hypomethylation and high expression**   TOP2A      topoisomerase (DNA) II alpha                     76       Up-regulated        \<1E-12
                                            MAD2L1     MAD2 mitotic arrest deficient-like 1 (yeast)     38       Up-regulated        1.62E-12
                                            FEN1       flap structure-specific endonuclease 1           35       Up-regulated        1.62E-12
                                            EPRS       glutamyl-prolyl-tRNA synthetase                  35       Up-regulated        \<1E-12
                                            EXO1       exonuclease 1                                    33       Up-regulated        \<1E-12
                                            MCM4       minichromosome maintenance complex component 4   32       Up-regulated        1.62E-12
                                            PTTG1      pituitary tumor-transforming 1                   30       Up-regulated        1.62E-12
                                            RRM2       ribonucleotide reductase regulatory subunit M2   29       Up-regulated        \<1E-12
                                            PSMD14     proteasome 26S subunit, non-ATPase 14            28       Up-regulated        \<1E-12
                                            CDKN3      cyclin dependent kinase inhibitor 3              28       Up-regulated        1.62E-12
                                            H2AFZ      H2A histone family member Z                      27       Up-regulated        \<1E-12
                                            CCNE2      cyclin E2                                        26       Up-regulated        1.10E-16
  **Hypermethylation and low expression**   EGFR       epidermal growth factor receptor                 37       Down-regulated      2.20E-16
                                            FGF2       fibroblast growth factor 2                       34       Down-regulated      \<1E-12
                                            BCL2       BCL2, apoptosis regulator                        29       Down-regulated      5.40E-04
                                            PIK3R1     phosphoinositide-3-kinase regulatory subunit 1   27       Down-regulated      1.62E-12

###### 

Biological function of modules identified by Cytoscape.

  Category                              Module   Function description                                                                      P Value    Nodes   Genes
  ------------------------------------- -------- ----------------------------------------------------------------------------------------- ---------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hypomethylation and high expression                                                                                                                         
                                        1        Cell division                                                                             3.30E-06   22      EXO1, RAD51AP1, SHCBP1, PBK, TTK, MCM4, KIF14, ECT2, RRM2, PTTG1, NEK2, CENPF, CDKN3, MAD2L1, UBE2T, E2F8, DTL, CCNE2, ZWINT, FEN1, ASPM, TOP2A
                                        2        Negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle   3.80E-13   10      PSMB5, BUB3, UCHL5, PSMD4, PSMC2, SHFM1, PSMD1, STAMBP, PSMD14, PSMB4
                                        3        mRNA splicing, via spliceosome                                                            4.20E-07   25      POLD1, PQBP1, PUSL1, MYLIP, H2AFZ, POLR2K, UBE2Q1, UBE2H, U2AF2, CDC5L, NBN, MRE11A, EPRS, TCEB1, SOCS1, SF3B4, RPL7, RBM8A, RSRC1, RAD54B, FBXO22, SNRPB, FBXO6, BRIP1, SEC61A1
                                        4        tRNA aminoacylation for protein translation                                               5.00E-08   5       GARS, TARS, DARS2, CCT5, IARS2
                                        5        Mitochondrial translational elongation                                                    6.60E-17   8       MRPS5, MRPS14, MRPL42, GFM2, CHCHD1, MRPS34, MRPL24, MRPL19
  Hypermethylation and low expression                                                                                                                         
                                        1        Mesenchyme migration                                                                      2.40E-03   9       ITGA1, MYL9, MYLK, ACTG2, TPM2, CNN1, ACTA2, LMOD1, TAGLN
                                        2        Protein ubiquitination                                                                    3.60E-06   7       CUL3, ANAPC4, KLHL21, FBXL5, FBXO2, TRIM9, HUWE1
                                        3        Negative regulation of phosphorylation                                                    4.80E-03   5       CDKN1C, GRB10, PEG3, MEST, PLAGL1
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